Actuate Therapeutics’ Elraglusib Receives the US FDA’s Rare Pediatric Disease Designation for Treating Ewing Sarcoma
Shots:
- The US FDA has granted rare pediatric disease designation to elraglusib for treating Ewing sarcoma (EWS). The company is eligible for a Priority Review Voucher (PRV), if approved
- The P-I/II (Actuate-1902) study is assessing elraglusib +/- (irinotecan +/- temozolomide)/(cyclophosphamide + topotecan) in pediatric patients with r/r EWS and related sarcomas, with topline data anticipated in H2’25
- Elraglusib (9-ING-41) inhibits GSK-3β responsible for cancer growth and drug resistance and has a potential to treat various cancers by targeting tumor signaling and immune response
Ref: Actuate Therapeutics | Image: Actuate Therapeutics
Related News:- Genascence Corporation’s GNSC-001 Receives the US FDA’s Fast Track Designation for Treating Osteoarthritis (OA) of the Knee
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Click here to read the full press release
Disha is a content writer at PharmaShots. She is passionate and curious about recent updates and developments in MedTech and Pharma industry. She covers news related to clinical trial results and updates. She can be contacted at connect@pharmashots.com.
